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Hyaluronanmers to pulmonary surfactants improves surface activity in experiments both in
vitro and in vivo. Although the viscosity of surfactants has been investigated, the viscosity of surfactant
polymer mixtures has not. In this study, we have measured the viscosities of Survanta and Infasurf with and
without the addition of polyethylene glycol, dextran or hyaluronan. The measurements were carried out over
a range of surfactant concentrations using two concentrations of polymers at two temperatures. Our results
indicate that at lower surfactant concentrations, the addition of any polymers increased the viscosity.
However, the addition of polyethylene glycol and dextran to surfactants at clinically used concentrations can
substantially lower viscosity. Addition of hyaluronan at clinical surfactant concentrations slightly increased
Infasurf viscosity and produced little change in Survanta viscosity. Effects of polymers on viscosity correlate
with changes in size and distribution of surfactant aggregates and the apparent free volume of liquid as
estimated by light microscopy. Aggregation of surfactant vesicles caused by polymers may therefore not only
improve surface activity as previously shown, but may also affect viscosity in ways that could improve
surfactant distribution in vivo.
Published by Elsevier B.V.1. IntroductionThe viscosity of lung surfactant is dependent on its molecular
composition, its microstructure, the interactions between compo-
nents and the environmental conditions. Viscosity is believed to
inﬂuence the rate, extent and uniformity of distribution of surfactant
in the lungs [1–3]. The early stage of surfactant distribution, occurring
in the upper one-third of approximately 18 generations or bifurcations
of the airway system, is rapid and controlledmainly by surfactant bulk
viscosity. A lower value allows a more uniform and rapid distribution
of the instilled surfactant with less initial loss due to coating of the
upper airways [1,4,5]. The distribution of surfactant into the small
airways and the alveoli, occurring in the remaining dozen or so
generations, is controlled by differences in surface tension of various
ﬂuids and components in the pulmonary system (Marangoni ﬂow) [5],
or by surface viscosity, not by bulk viscosity and therefore not studied.
Our previous work and that of others have shown the beneﬁts in
vitro and in vivo of adding an ionic polymer like hyaluronan (HA), or
nonionic polymers like polyethylene glycol (PEG) or dextran to
exogenous surfactant. Beneﬁts include improvements in surface
activity and lung function [6–14]. Although the viscosity of a variety
of surfactants has been studied [3,15], changes in viscosity after
addition of polymers have not been investigated. Of concern isital, Department of Pediatrics,
, USA. Tel.: +1 415 206 3080;
.V.whether added polymers would increase viscosity of therapeutic
surfactants to the degree that distribution of surfactant in the lung
might be affected. For this reason, wemeasured surfactant viscosity in
the presence or absence of the polymers that we have found to be
beneﬁcial including those concentrations of surfactant and polymer
thatmaybe clinically relevant. In the event that someof thesemixtures
have lower viscosity than the surfactant itself, then the lowered
viscosity may be a contributing factor to the in vivo improvements in
lung function previously attributed to enhanced surface activity.
Survanta and Infasurf were selected not only because they are both
in widespread clinical use but also because their viscosities differ
appreciably, as previously reported [15]. Our aim was to measure and
characterize the viscous properties of therapeutic surfactantswith and
without polymers under a range of conditions. Light microscopy of the
differentmixtureswas carried out to ﬁndwhether correlations existed
between viscosity and the microstructure of surfactant dispersions.
2. Methods
2.1. Materials
Survanta (Ross Laboratories, Columbus, OH) and Infasurf (Forest
Laboratories, New York, NY) were obtained through hospital pharma-
cies. PEG (10 kDa) and dextran (10 kDa) were purchased from Sigma
Chemical (St. Louis, MO). HA (250 kDa), produced by streptococci, was
obtained fromGlycoMedResearch, Inc. (Hastings-on-Hudson,NY). The
buffer used was 0.9% NaCl with 2.5 mM HEPES and 2.5 mM CaCl2
adjusted to a pH of 7.0.
Table 1
Viscosity and aggregation state of surfactants with and without polymers
Surfactant Viscosity (cSt) Aggregation % apparent
free volume
23°C 37°C 23°C 37°C 23°C 37°C
Infasurf 35 mg/mL 2.5±0.3 3.9±0.5 + − 38±3 n.d.
+ Dextran 2.7±0.1 1.6±0.1 ++ ++ 47±3 55±6
+ PEG 4.6±0.1 2.4±0.1 +++ +++ 63±6 62±7
+ HA 6.8±0.1 5.1±0.1 ++ ++ 46±5 30±5
Survanta 25 mg/mL 92.7±5.4 32.5±4 − − b1 b1
+ Dextran 18.2±0.5 12.3±0.1 +++ ++ 29±12 n.d.
+ PEG 6.2±0.1 3.9±0.1 +++ +++ 49±11 52±6
+ HA 87.8±0.4 32.7±0.3 − − b1 b1
Values are means±s.d. after 3 determinations (viscosity) or averaging 5 frames (free
volume).
n.d. indicates not determined. More + indicates greater aggregation.
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Kinematic viscosity measurements were made with Cannon–
Manning semi-microviscometers (State College, PA) sizes 100, 150
and 200. The sizes correspond to different ranges of viscosity with
some overlap that were suitable for our measurements. Time required
for ﬂuid to drain by gravity through a viscometer tube was measured,
and this time was converted to a value of kinematic viscosity using a
calibration constant supplied by the manufacturer and veriﬁed in our
laboratory using standard ﬂuids. The kinematic viscosity can be
converted to dynamic (absolute) viscosity by multiplying by the
density of the ﬂuid. This method of determining viscosity was chosen
because of its relevance to distribution of surfactant in the upper
airways that is controlled by gravity as well as by airﬂow upon
inhalation. Measurements were also made using different sized
viscometer tubes for surfactant mixtures and no signiﬁcant differ-
ences occurred. This conﬁrms the assumption that the kinematic
viscosity varies slowly with shear rate in this regime. The surfactants
were used as supplied (Survanta 25 mg phospholipid/mL; Infasurf
35 mg/mL) or diluted with the buffer deﬁned in Materials above to
concentrations of 1.25, 2.5, 5, or 12.5, and for Infasurf, 25 mg/mL. The
concentrations (w/v), and molecular weights of polymers used were
those found effective in previous studies; that is, PEG 10 kDa, 5%;
dextran 10 kDa, 5%; and HA 250 kDa, 0.25% [7–9,16]. The viscosity of
mixtures with half these polymer concentrations was also measured.
In addition, buffer with higher polymer concentrations (without
surfactant) was studied to aid in understanding the dependence of
viscosity on free volume of liquid. Polymers in dry powder formwere
combined with the surfactant at indicated concentrations, then
dispersed byVortex in 5 s bursts until uniform in appearance.Mixtures
weremaintained at room temperature for approximately 60min, with
a brief Vortex again before usage. Measurements were made after the
viscometer with sample was placed in a temperature-maintained
circulating water jacket for 10 min at 23 or 37°C. Three measurements
were carried out for each sample mixture and results averaged.
2.3. Microscopy
Samples of Infasurf (35 and 12.5 mg/mL) and Survanta (25 and
12.5 mg/mL) were examined with and without the addition of
polymers. Dextran, PEG or HA was added in concentrations of 5%, 5%
and 0.25% respectively. Ten microliters of surfactant or surfactant
polymer mixture, preincubated for 20 min at either 23 or 37°C, were
sandwiched between a slide and a cover glass and examined by lightFig. 1. Viscosity of Infasurf in the absence and presence of polymers. Viscosity of Infasurf
alone (black circles) or with dextran 5% (open circles), PEG 5% (squares) or 0.25% HA
(triangles) versus phospholipid concentration, determined at 23°C (left panel) or 37°C
(right panel). Lines are visual guides.microscopy. Photomicrographs were ﬁrst examined to ﬁnd whether
ﬂocculation was similar to previously reported results with similar
polymer-surfactant mixtures studied using freeze fracture electron
microscopy or spectroscopy [17,18]. Images were then processed to
improve contrast and converted into two-component (surfactant
aggregates and apparent free volume) two-dimensional maps. Five
ﬁelds per surfactant mixture were processed, measured and averaged
to calculate the apparent fraction occupied by aggregates or by free
volume using ImageJ Java software (http://rsbweb.nih.gov/ij/). The
average size of surfactant aggregates was estimated by measuring the
length of at least 50 aggregates taken from a number of ﬁelds per
suspension.
2.4. Experimental data acquisition and analysis
The viscosity measurements andmicroscopic analysis of surfactant
structures were repeated with several independent surfactant batches
that showed similar qualitative behavior. Results shown are repre-
sentative experiments, where different measures are compared for
samples from the same surfactant batch, after averaging three
different determinations. The data were analyzed by one or two-
way repeatedmeasures of variance (ANOVA) using SigmaStat software
(SPSS Science Chicago, IL). Comparisons between pairs of groups were
done using the Tukey test for multiple comparisons. A p value ≤0.05
was considered statistically signiﬁcant. Errors in the experimental
determination of viscosity in low viscosity suspensions (b10 cSt) were
of the order of a few percent and are not indicated in the ﬁgures.
3. Results
3.1. Viscosity of Infasurf in the absence or presence of polymers
Viscosity of Infasurf was temperature and concentration depen-
dent as shown in Fig. 1 and Table 1. At lipid concentrations below
10 mg/mL, the viscosity of Infasurf suspensions was only slightly
higher than that of the buffer alone (Table 2), but the viscosity
increased substantially at the highest concentrations of Infasurf
tested, 25 or 35 mg/mL. Interestingly, this increase in viscosity was
markedly greater at 37 than at 23°C, as was previously noted by King
et al. [3,15]. In fact, the low initial viscosity of Infasurf suspensions at
35mg/mL at 23°C increased signiﬁcantly with incubation time at 37°C,
so that after 20 min, the viscosity rose by an order of magnitude to
34 cSt (Fig 2).
When PEG, dextran or HA was added to Infasurf at various
concentrations, differing effects were observed. At low surfactant
concentrations, addition of polymers increased viscosity to values
approximating those of the corresponding polymer-containing buffer
as determined in the absence of surfactant (Table 2). Dilute Infasurf
with polymer mixtures increased in viscosity in the following order:
Table 2
Viscosity of polymer-containing media
Viscosity (cSt)a
23 °C 37 °C
Buffer 1.1 0.8
+ dextran 2.5% 1.2 0.9
+ dextran 5% 1.4 1.0
+ dextran 10% 2.6 1.9
+ dextran 15% 3.1 2.3
+ PEG 2.5% 1.2 0.9
+ PEG 5% 2.4 1.6
+ PEG 10% 5.1 3.8
+ PEG 15% 11.2 8.4
+ HA 0.125% 1.7 1.2
+ HA 0.25% 2.4 1.6
a Values are means using 3 independent measurements, s.d. were in all cases on the
order of 1%.
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quite low. However, at or near concentrations of surfactants used
clinically, polymers produced effects on Infasurf viscosity that could
not be predicted from the differences in viscosity of the polymer
solutions themselves or from dilute Infasurf with polymer mixtures.
At 23°C, 5% dextran or 5% PEG increased the viscosity of the highest
concentrations of Infasurf to around 2.5 and 4.5cSt, respectively,
signiﬁcantly higher than the viscosity measured for a corresponding
buffer polymer solution without Infasurf (pb0.001). HA increased
viscosity of Infasurf to around 7cSt for surfactant concentrations of 25
or 35 mg/mL, three times higher than the viscosity of HA with buffer
(pb0.001). When measurements were made of polymers with highly
concentrated Infasurf at 37°C, HA increased the viscosity of Infasurf to
around 5cSt, but PEG and dextran both produced a substantial
decrease on measured viscosity, markedly lower than that of Infasurf
in the absence of polymers at the same temperature (pb0.001). A
striking observation was that the presence of any of the three
polymers eliminated the increase of viscosity that occurred in Infasurf
after incubation at 37°C (see Fig. 2). For example, after 30 min
incubation of 35 mg/mL Infasurf with PEG, dextran or HA, viscosity
values were 2.5, 2.0 or 7.5cSt, respectively compared to 41 cSt for
Infasurf alone.
3.2. Viscosity of Survanta in the absence or presence of polymers
The viscosity of Survanta was highly concentration dependent,
with the largest increase occurring between 12.5 and 25 mg/mL: at
12.5 mg/mL, the viscosity was 8cSt at 23°C and 3cSt at 37°C comparedFig. 2. Effect of temperature on the viscosity of Infasurf with and without polymers.
Viscosity of Infasurf alone (black circles) or with dextran 5% (open circles), PEG 5%
(squares) or 0.25% HA (triangles) versus time of incubation at 37°C. Time=0
corresponds to 23°C. Lines are visual guides.to 90cSt and 32cSt respectively at 25 mg/mL. Survanta had
consistently higher viscosity than Infasurf at equal concentration at
23 or 37°C, and at the highest concentrations, the viscosity value of
Survanta greatly exceeded that of Infasurf (Fig. 3). Also, in contrast to
Infasurf, Survanta viscosity at any concentration was always lower at
37°C than at 23°C and did not change with time at either temperature.
Addition of polymer to Survanta caused effects on viscosity that
depended on the concentration of surfactant also, but were somewhat
different than observed for Infasurf. PEG and dextran increased the
viscosity of dilute Survanta at 23°C from around 1 to about 1.5 and
2.5cSt, respectively. However, for concentrations of surfactant above
10 mg/mL, the addition of these two polymers produced a consider-
able reduction of viscosity at 23°C. At 37°C, PEG and dextran had
qualitatively similar effects on Survanta viscosity, increasing it slightly
at low surfactant concentrations but reducing it markedly (pb0.001)
at surfactant concentrations higher than 10 mg/mL (Fig. 3). When HA
was added to dilute Survanta, its viscosity was slightly reduced at 23°C
and slightly increased at 37°C, with values at or below 2cSt. At
high Survanta concentrations, such as those used clinically, HA
produced little change in viscosity, at either temperature (Fig. 3 and
Table 1).
When lower concentrations of dextran or PEG (2.5% w/v) were
added to either surfactant, the effects on viscosity were qualitatively
similar to those found with the higher concentrations used above
(data not shown).
3.3. Effect of polymers on aggregation of Infasurf and Survanta
Microscopy studies were carried out on Infasurf at 12.5 and
35 mg/mL and on Survanta at 12.5 and 25 mg/mL. Results at
12.5 mg/mL were qualitatively similar to the higher concentrations
and are not shown. Fig. 4 shows photomicrographs of Infasurf
35 mg/mL in the absence or presence of polymers preincubated at
23 or 37°C. Signiﬁcant differences in aggregation are apparent. At
23°C, Infasurf suspensions were composed of small homogeneously
distributed, spherically shaped surfactant aggregates, with an
average diameter of 2.1±0.8 μm (see contrast-increased detail in
Infasurf picture, Fig. 4). These aggregates were completely inter-
mingled and occasionally associated to form dispersed clusters. The
apparent free liquid area as projected in two-dimensional pictures
(see corresponding two-dimensional map, Fig. 4), occupies 35–40%
of the total area. These surfactant-free areas are extrapolated into
three dimensions and termed free volume.Fig. 3. Viscosity of Survanta in the absence and presence of polymers. Viscosity of
Survanta alone (black circles) or with dextran 5% (open circles), PEG 5% (squares) or
0.25% HA (triangles) versus phospholipid concentration, determined at 23°C (left panel)
or 37°C (right panel). Inserts: rescaling of the plots at low Survanta concentrations.
Lines are visual guides.
Fig. 4.Microstructure of Infasurf in the absence and presence of polymers. Micrographs of Infasurf suspensions at 35 mg/mL, in the absence or presence of dextran 5%, PEG 5% or HA
0.25% preincubated at 23 °C (upper pictures) or 37 °C (lower pictures). Slides were taken under an optical microscope as described in Methods with scale bars representing 20 μm.
Insert in the Infasurf picture was magniﬁed an additional three times and contrast-enhanced to illustrate the aggregate structure of this surfactant. Below the micrographs are two
dimensional maps representing the projection of the apparent volume occupied by either surfactant aggregates (grey) or free liquid (white).
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heterogeneous, with surfactant aggregates forming into large rela-
tively compact clusters of 40±22 or 49±26 μm average dimension
producing approximately 65% or 50% free volume respectively (see
Table 1). Infasurf in the presence of HA also yielded a partial clustering
of surfactant components, producing around 45% free volume.
However, in contrast to PEG or dextran, HA-containing Infasurf
exhibited interconnected complexes, forming a continuous network
throughout the entire ﬁeld.
The microscopic structure of Infasurf alone changed signiﬁcantly
with time at 37°C compared with 23°C. Surfactant complexes at
physiological temperature lost most of their optical contrast and
presented a rather uniform appearance with almost no free volume
after 20 min. In the presence of polymers, Infasurf complexes also
showed less contrast at 37 than at 23°C, but these structures were of
similar size and occupied similar volume fractions as those observed
at 23°C. In the presence of PEG or dextran, Infasurf aggregates were
large and dispersed in a continuous free volume, while in the presence
of HA, all the aggregates were interconnected with only around 30%
dispersed free volume (Fig. 4 and Table 1).
Microscope data on the aggregation of Survanta at 25 mg/mL, in
the absence or presence of polymers, is shown in Fig. 5. In contrast to
Infasurf, Survanta by itself did not show, either at 23 or 37°C, the
presence of discrete identiﬁable structures, but appeared as a
continuous matrix with no clear free volume. Addition of PEG or
dextran induced a clustering effect on Survanta suspensions, both
at 23 and 37°C. PEG was more effective at inducing this effect, causing
Survanta to form large aggregate structures (whose polymorphic
nature precluded quantiﬁcation of average size), with about 50%
free volume, either at 23 or 37°C. Addition of dextran also induced
clusters of large complexes in Survanta, generating around 30% freevolume at 23°C. At 37°C, dextran produced clustering of surfactant
complexes but the optical contrast of the resulting aggregates
was too low to allow calculation of the free volume, although it
appeared to be less than that with PEG. Unlike results with PEG or
dextran, the addition of HA to Survanta did not produce observable
changes, with the HA Survanta mixtures having the same homo-
geneous and continuous matrix-like structures seen in the absence of
polymer.
4. Discussion
Our results indicate that at the same concentration, viscosity of
Survanta was always higher than that of Infasurf. This ﬁnding has
been attributed to differences in composition and structure [3,15].
Survanta contains palmitic acid, tripalmitin and additional DPPC but
no cholesterol and much less SP-B compared to Infasurf [19].
Survanta viscosity rose by an order of magnitude as concentration
increased from 12.5 to 25 mg/mL at either 23°C or37 °C. The large
increase in viscosity for Infasurf at 37°C, was also observed by King
et al. [3,15]. This effect grew to an order of magnitude increase
in viscosity after 20 min at 37°C. These large changes in viscosity
cannot be explained by a simple extrapolation from lower concen-
trations and support the hypothesis of substantial morphological
and rheological changes occurring at higher concentrations and
temperature.
A major ﬁnding of this study is that when either surfactant at
clinically used concentrations had polymer added, the viscosity was
decreased or had little change. At a concentration of 25 mg/mL, the
addition of dextran or PEG lowered the viscosity of Survanta by
approximately an order of magnitude. At high Infasurf concentrations,
the addition of dextran, PEG, or HA reversed the higher viscosity
Fig. 5.Microstructure of Survanta in the absence and presence of polymers. Micrographs of Survanta suspensions at 25mg/mL, in the absence or in the presence of dextran 5%, PEG 5%
or HA 0.25% preincubated at 23 °C (upper pictures) or 37 °C (lower pictures). Slides were taken under an optical microscope as described in Methods with scale bars representing
20 μm. Below some of the micrographs a two dimensional map represents the projection of the apparent volume occupied by surfactant aggregates (grey) or free liquid (white).
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viscosity with time at 37 °C is also eliminated by addition of any of the
three polymers.
The ﬁnding that lower concentrations of non-ionic polymers (2.5%
w/v) yielded qualitatively similar results as those at higher concen-
tration (5% w/v) implies that there is no evident polymer threshold
concentration for the observed effects, at least down to half
concentration. Since higher amounts of polymer in surfactant can
lead to increased osmotic pressure, causing lung edema [20,21], the
observation that lower concentrations of PEG or dextran can reduce
viscosity may prove useful for eventual ﬁne-tuning of clinical
surfactant polymer mixtures.
We have found that the addition of PEG or dextran to the
surfactants causes lipid aggregation and clustering of aggregates
that may be due to depletion forces caused by the exclusion of
polymer from the vicinity of surfactant aggregates [22–25]. This
clustering creates an increase of surfactant-free space (free volume)
within the surfactant suspension (Figs. 4, 5) and also promotes
adsorption of large surfactant components to the air–liquid interface
thereby improving resistance of surfactant to inactivation by various
inhibitors [11–14]. Surfactant suspensions, with or without polymers,
can be considered as complex colloids composed of a solid-like phase
with different sized particle structure and an aggregate-free liquid
volume. At low surfactant concentrations, the rheological behavior of
the suspensions is dominated by the free liquid phase, and the
viscosity approaches that of the buffer plus polymer, if present. At
higher surfactant concentrations, those relevant to clinical use,
surfactant suspensions with low viscosity have a dominant contin-
uous surfactant-free liquid phase (free volume), while more viscous
suspensions have an interconnected matrix of surfactant lipid/protein
complexes. Surfactant viscosity would then be expected to follow a
behavior similar to that already described for other colloidal
suspensions, including an exponential increase in viscosity at colloidal
densities above a certain threshold, associated with close particle
packing [26]. Infasurf suspensions at 23°C had similar proportions ofsurfactant aggregates and free volume, while after incubation at 37°C,
the entire suspension became more homogeneous and the free
volume diminished in parallel with the progressive increase in
viscosity. This observation supports an association between changes
in microscopic structures of surfactant suspensions and their
rheological behavior. The reduction of surfactant viscosity caused by
polymers like PEG or dextran correlates with their ability to change a
diffuse three-dimensional surfactant matrix into a mostly ﬂuid
suspension (large free volume) of large aggregate clusters. This
clustering occurred with the addition of PEG or dextran to the
surfactants, but not with HA, in agreement with results from freeze
fracture electron microscopy [18] and measurements of turbidity [17].
A similar mechanism may lie behind the low viscosities associated
with the large aggregation of surfactants caused by addition of other
polymers like chitosan [27]. Determination of viscosity of buffered
solutionswith different polymer concentrations, without surfactant, is
shown in Table 2. These data illustrate that much of the decrease in
viscosity with addition of polymer at high surfactant concentration is
attributable to the generation of large free volume. This is especially
evident in the case of PEG where the viscosity at 10% polymer
concentration alone is close to that of surfactant plus 5% polymer. Ten
percent is approximately the effective polymer concentration since
the free volume is close to 50%. Adding HA to the surfactants produced
changes in the microscopic structure that were of a different nature
than changes induced by PEG or dextran, and were associated with no
clear decrease in viscosity. It has been shown that HA can interact with
phospholipids to create large ﬁbril-like networks [28,29]. Our
microscope observations indicate that surfactant with HA produces
a reorganization of surfactant components to form an interconnected
matrix of structures that occupies the whole suspension. This was
particularly evident when HAwas added to Infasurf (see Fig. 4). Such a
matrix or network could stabilize the surfactant structures within the
suspension by sequestering the liquid portion. Stabilization could
prevent the homogenizing effect that occurs in polymer-free Infasurf
at 37°C. The differing viscosity effects on Infasurf or Survanta when
637K.W. Lu et al. / Biochimica et Biophysica Acta 1788 (2009) 632–637PEG or dextran is added compared to addition of HA support the
previously reported hypothesis that non-ionic and anionic polymers
produce beneﬁcial effects upon addition to surfactant by different
mechanisms [7,8,18].
The surface viscosity of Survanta has been previously studied as a
function of surface pressure [30,31]. At low compression ratios, when
Survanta ﬁlms contain a signiﬁcant fraction of ﬂuid phase, the ﬁlms
showed low surface viscosity that escalated to very high values when
the compression-promoted solid phase reached the percolation limit,
i.e., enough to interconnect the whole ﬁlm. Our results suggest that a
similar correlation may exist between bulk viscosity of surfactant
suspensions and their aggregation state.
In summary, our results have shown that the addition of polymer
to Infasurf and Survanta can either lower the viscosity (PEG and
dextran) or have little effect on it (HA) at clinically used concentra-
tions and/or physiological temperature. This ﬁnding not only answers
the initial concern that the addition of polymer might increase
viscosity to a degree that would adversely affect distribution in the
upper airways but also suggests that the reduction of viscosity with
polymer added could in fact aid in rapid and uniform surfactant
distribution when introduced as a bolus in the trachea. This viscosity
decrease could be responsible, in part, for the beneﬁcial effects
previously reported in vivo [8–10,16]. It has also been shown that
aggregation and clustering of surfactant lipids due to addition of PEG
or dextran correlates with a decrease of viscosity.
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